Literature DB >> 24238694

Management of infection in systemic lupus erythematosus.

Savino Sciascia1, Maria Jose Cuadrado, Mohammed Yousuf Karim.   

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterised by abnormal autoantibody production and clearance. This immunological background has been suggested to play a role in the susceptibility of SLE patients to infection. Moreover, drugs (most of them immunosuppressive or immunomodulating agents) used in the treatment of moderate and severe lupus give rise to a tendency for infections, including opportunistic ones. Infections may mimic the exacerbations of SLE, leading to confusion over the diagnosis and appropriate treatment. Despite increased awareness of this problem, infections remain a major source of morbidity and mortality in SLE. There are various strategies which can be applied to try and reduce the risk of infection in SLE patients. Options include vaccinations, antibiotic/antiviral prophylaxis and intravenous immunoglobulins.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bacterial viral fungal flare; Immunoglobulin; Vaccination; Vaccine antibiotic prophylaxis

Mesh:

Substances:

Year:  2013        PMID: 24238694     DOI: 10.1016/j.berh.2013.07.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  12 in total

1.  Lupus or syphilis? That is the question!

Authors:  Joana Azevedo Duarte; Celia Coelho Henriques; Carolina Sousa; José Delgado Alves
Journal:  BMJ Case Rep       Date:  2015-06-04

Review 2.  The Cutaneous Spectrum of Lupus Erythematosus.

Authors:  Simone Ribero; Savino Sciascia; Luca Borradori; Dan Lipsker
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

3.  Medication use among pregnant women with systemic lupus erythematosus and general population comparators.

Authors:  Kristin Palmsten; Julia F Simard; Christina D Chambers; Elizabeth V Arkema
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

Review 4.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

5.  Levels of serum procalcitonin and C-reactive protein for evaluating pulmonary bacterial infection in patients with lupus erythematosus.

Authors:  Jing Gao; Lei Zhang; Xin Zhang; Shi-Long Zhao; Sheng-Yun Liu; Li-Hua Xing
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

Review 6.  Pyomyositis in a patient with systemic lupus erythaematosus and a review of the literature.

Authors:  Somchai Meesiri
Journal:  BMJ Case Rep       Date:  2016-04-18

Review 7.  Roles of B Cell-Intrinsic TLR Signals in Systemic Lupus Erythematosus.

Authors:  Kongyang Ma; Jingyi Li; Yongfei Fang; Liwei Lu
Journal:  Int J Mol Sci       Date:  2015-06-09       Impact factor: 5.923

8.  Association between Staphylococcus aureus nasal carriage and disease phenotype in patients affected by systemic lupus erythematosus.

Authors:  Fabrizio Conti; Fulvia Ceccarelli; Giancarlo Iaiani; Carlo Perricone; Alessandra Giordano; Luigino Amori; Francesca Miranda; Laura Massaro; Viviana Antonella Pacucci; Simona Truglia; Gabriella Girelli; Azis Fakeri; Gloria Taliani; Chiara Temperoni; Francesca Romana Spinelli; Cristiano Alessandri; Guido Valesini
Journal:  Arthritis Res Ther       Date:  2016-07-30       Impact factor: 5.156

Review 9.  Infection and Lupus: Which Causes Which?

Authors:  Sarah Doaty; Harsh Agrawal; Erin Bauer; Daniel E Furst
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.686

10.  Prospective Evaluation of Procalcitonin, Soluble Triggering Receptor Expressed on Myeloid Cells-1 and C-Reactive Protein in Febrile Patients with Autoimmune Diseases.

Authors:  Chou-Han Lin; Song-Chou Hsieh; Li-Ta Keng; Ho-Sheng Lee; Hou-Tai Chang; Wei-Yu Liao; Chao-Chi Ho; Chong-Jen Yu
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.